Note: This document contains side effect information about ado-trastuzumab emtansine. Some of the dosage forms listed on this page may not apply to the brand name Kadcyla.
Common side effects of Kadcyla include: increased serum bilirubin, increased serum transaminases, cough, decreased platelet count, dyspnea, fatigue, fever, peripheral neuropathy, and thrombocytopenia. Other side effects include: chills. See below for a comprehensive list of adverse effects.
Applies to ado-trastuzumab emtansine: intravenous powder for solution
Intravenous route (Powder for Solution)
Do not substitute ado-trastuzumab emtansine with or for trastuzumab. Hepatotoxicity, liver failure, reductions in left ventricular ejection fraction, and death have occurred in ado-trastuzumab emtansine-treated patients. Monitor hepatic function and left ventricular function before beginning treatment and before each dose. Modify, hold, or discontinue treatment as necessary. Exposure to ado-trastuzumab emtansine during pregnancy can result in embryo-fetal harm. Advise patients of these risks and the need for effective contraception.
Along with its needed effects, ado-trastuzumab emtansine (the active ingredient contained in Kadcyla) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.
Check with your doctor or nurse immediately if any of the following side effects occur while taking ado-trastuzumab emtansine:
Incidence not known
Some side effects of ado-trastuzumab emtansine may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:
Applies to ado-trastuzumab emtansine: intravenous powder for injection
Common (1% to 10%): Left ventricular dysfunction, hypertension, peripheral edema
Very common (10% or more): Rash (12%)
Common (1% to 10%): Pruritus, alopecia, nail disorder, palmar-plantar erythrodysesthesia syndrome, urticaria
Very common (10% or more): Nausea (40%), constipation (24%), vomiting (20%), diarrhea (20%), dry mouth (16%), abdominal pain (16%), stomatitis (15%), stomatitis
Common (1% to 10%): Dyspepsia, gingival bleeding
Very common (10% or more): Urinary tract infection (12%)
Very common (10% or more): Hemorrhage (35%), thrombocytopenia (25%), anemia (15%), hemorrhage
Common (1% to 10%): Neutropenia, leucopenia
Very common (10% or more): Transaminases increased (12%)
Common (1% to 10%):
Uncommon (0.1% to 1%): Hepatotoxicity, hepatic failure, nodular regenerative hyperplasia, portal hypertension
Rare (0.01% to 0.1%): Portal hypertension, hepatic failure, nodular regenerative hyperplasia
Common (1% to 10%): Hypersensitivity
Common (1% to 10%): Immunogenicity
Very common (10% or more): Hypokalemia (11%)
Common (1% to 10%): Blood alkaline phosphatase increased
Very common (10% or more): Musculoskeletal pain (36%), arthralgia (19%), myalgia (13%)
Very common (10% or more): Headache (28%), peripheral neuropathy (23%), asthenia, chills
Common (1% to 10%): Dizziness, dysgeusia, memory impairment
Common (1% to 10%): Dry eye, conjunctivitis, blurred vision, lacrimation increased
Very common (10% or more): Fatigue (37%), pyrexia (23%), asthenia (16%), chills (10%)
Very common (10% or more): Insomnia (12%)
Very common (10% or more): Epistaxis (24%), cough (20%), dyspnea (13%)
Uncommon (0.1% to 1%): Pneumonitis
Uncommon (0.1% to 1%): Injection site extravasation, infusion-related reactions
Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.
Source: Drugs.com Kadcyla